As of September 18, 2026, KIMS is trading at ₹809.85. The stock exhibits a mixed technical picture across different timeframes. Daily indicators suggest a potential weakening trend, with the Super Trend indicator in a bearish state and the 5-day slope of the 20-day Simple Moving Average (SMA) showing a negative trend. However, the price remains above key daily moving averages including the 20-day Exponential Moving Average (EMA) and 200-day SMA. In contrast, weekly and monthly timeframes present a more constructive outlook, with Super Trend indicators in a bullish state and the price trading above relevant moving averages on both periods. Recent active patterns include a "Bullish Engulfing Reversal" and "Morning Star" on the monthly and weekly charts respectively, suggesting potential upside.

The stock is currently positioned near its nearest support level at ₹806.25, which is approximately 0.44% below the current price. Key resistance is observed around ₹820.65, about 1.33% higher. The stock's recent trading history includes a "wide intraday range" anomaly on September 17, 2026, with a significant upward price movement. Volatility remains a factor, with an annualized volatility of 32% and a current drawdown of -5%.

Krishna Institute of Medical Sciences Limited (KIMS) has been active in investor engagement and strategic expansion over the past week. The company announced an Operations and Management Agreement with Sarvottam Health Care Private Limited (SHPL) on September 10, 2026. This five-year agreement, with an option for a further five-year extension, involves KIMS managing SHPL's 183-bed hospital in Kakinada, Andhra Pradesh. Under this arrangement, KIMS will receive a revenue fee equivalent to 9% of SHPL's total net revenue, aiming to expand KIMS's regional presence.

In parallel, KIMS has scheduled multiple investor and analyst meetings. These include a meeting hosted by Emkay Global Group on September 10, 2026, and participation in the J.P. Morgan India Conference on September 21, 2026, and the Anand Rathi Annual Flagship Conference G-200 Summit 2026 on September 22, 2026. The company has stated that no unpublished price-sensitive information will be disclosed during these sessions, and schedules are subject to change.

As of September 18, 2026, Krishna Institute of Medical Sciences (KIMS) on the NSE saw its stock price increase to ₹809.85 from a previous price of ₹791.85. The provided evidence does not detail any new filings or news developments for the company. The daily and weekly trends for the stock are not specified in the recent data.

Krishna Institute of Medical Sciences Limited (KIMS) has entered into an Operations and Management Agreement with Sarvottam Health Care Private Limited (SHPL) to manage SHPL's 183-bed hospital in Kakinada, Andhra Pradesh. This five-year agreement, with an option for a further five-year extension, will see KIMS receive a revenue fee equivalent to 9% of SHPL's total net revenue. This arrangement allows KIMS to expand its regional presence and manage hospital operations exclusively. The company also clarified on August 26, 2026, that reports from August 25, 2026, regarding a potential acquisition of a stake in Renova Hospitals for $52 million were false and baseless, stating no such discussions or agreements were in place. KIMS held its 24th Annual General Meeting on August 27, 2026, where financial statements for the year ended March 31, 2026, were adopted, and a director was re-appointed. Additionally, the company reported the allotment of 7,702,182 fully convertible warrants on August 19, 2026, following a preferential issue. KIMS has also scheduled several investor and analyst meetings in September 2026, including sessions at the J.P. Morgan India Conference on September 21, 2026, and the Anand Rathi Annual Flagship Conference on September 22, 2026. These meetings will not involve the disclosure of unpublished price-sensitive information.

Krishna Institute of Medical Sciences (KIMS) reported revenue from operations of ₹1,179.50 crore for Q1 FY2026-27. This represents an increase from the ₹1,074.60 crore reported in Q4 FY2025-26 and ₹997.70 crore in Q3 FY2025-26. Profit Before Tax (PBT) for Q1 FY2026-27 was ₹55.60 crore, a decrease from ₹68.60 crore in Q3 FY2025-26, although it showed an increase from ₹52.20 crore in Q4 FY2025-26. Finance costs have shown a consistent upward trend, rising from ₹56.80 crore in Q3 FY2025-26 to ₹83.40 crore in Q1 FY2026-27. Basic and Diluted Earnings Loss Per Share (EPS) from continuing operations stood at ₹1.04 per share in Q1 FY2026-27, reflecting a decrease from ₹1.33 per share in Q3 FY2025-26 and ₹1.06 per share in Q4 FY2025-26. The increasing finance costs alongside a fluctuating PBT warrant monitoring in relation to revenue growth.

Krishna Institute of Medical Sciences (KIMS) exhibits several technical indicators suggesting positive momentum across different timeframes. On a weekly basis, the stock is trading above its 20-day and 50-day Simple Moving Averages (SMAs), with both SMAs showing an upward slope. The Supertrend indicator is also in a bullish direction on the weekly chart. This trend is supported by a positive 6-month return of 21% and a Year-to-Date (YTD) return of 31%. While the daily trend shows the Supertrend indicator in a bearish direction, the price is currently above its 20-day Exponential Moving Average (EMA) and the EMA itself has a positive slope, indicating some underlying strength.

The company's stock is currently trading below its Super Trend indicator on a daily basis, which suggests a bearish short-term trend. While longer-term monthly trends remain bullish, the daily technicals indicate potential downward pressure. The stock has also experienced a drawdown of 5% from its recent peak, and its annualized volatility stands at 32%, highlighting a degree of price fluctuation. Furthermore, the Average True Range (ATR) at 2.59% suggests that the stock's price can move by this percentage on an average day, indicating potential for significant intraday price swings.